Yahoo Finance

GE HealthCare’s manganese-based MRI contrast agent shines in Phase I trial

GE HealthCare has announced positive results from a Phase I study of its manganese-based macrocyclic magnetic resonance imaging (MRI) contrast agent. Data from the first-in-human trial – presented at ...
Science Daily

Contrast-enhanced in-phase Dixon sequence impacts biopsy clip detection on breast MRI

Contrast-enhanced in-phase Dixon sequence could reduce the need for correlation among other imaging modalities to better identify areas of prior biopsy during breast MRI interpretation, according to a ...
Business Wire

Bayer’s investigational MRI contrast agent gadoquatrane meets primary and main secondary endpoints in pivotal Phase III studies

BERLIN--(BUSINESS WIRE)--Bayer, a global leader in radiology, today announced positive topline results of the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an ...
Business Wire

GE HealthCare Announces Completion of Phase I Subject Recruitment in Early Clinical Development Program for a First-of-its-Kind Macrocyclic Manganese-Based MRI Contrast Agent

Novel manganese-based macrocyclic Magnetic Resonance Imaging (MRI) agent could offer an alternative to gadolinium-based agents Manganese is a trace element naturally occurring in, and efficiently ...
EurekAlert!

Contrast-enhanced in-phase Dixon sequence impacts biopsy clip detection on breast MRI

Leesburg, VA, September 14, 2022—According to ARRS’ American Journal of Roentgenology (AJR), the contrast-enhanced in-phase Dixon sequence could reduce the need for correlation among other imaging ...